|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2011-5-26
|
|
pubmed:abstractText |
The primary objective of this sub-study, undertaken as an extension to the previously reported phase-I study, was to explore the feasibility, tolerability and pharmacokinetics (PK) of belinostat when administered by the oral route. Preliminary pharmacodynamic (PD) studies were also performed to enable comparison of the biological effects of the oral and intravenous formulations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1273-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20706839-Acetylation,
pubmed-meshheading:20706839-Administration, Oral,
pubmed-meshheading:20706839-Adult,
pubmed-meshheading:20706839-Aged,
pubmed-meshheading:20706839-Antineoplastic Agents,
pubmed-meshheading:20706839-Feasibility Studies,
pubmed-meshheading:20706839-Histone Deacetylase Inhibitors,
pubmed-meshheading:20706839-Histones,
pubmed-meshheading:20706839-Humans,
pubmed-meshheading:20706839-Hydroxamic Acids,
pubmed-meshheading:20706839-Leukocytes, Mononuclear,
pubmed-meshheading:20706839-Middle Aged
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
|
|
pubmed:affiliation |
Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom. nicola.steele@ggc.scot.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
